Joshua Schiffman, MD
The University of Utah's Joshua Schiffman, MD, discusses the use of molecular inversion probe (MIP) technology for studying copy number alterations in pediatric cancers
Scientists at the University of Utah, led by Dr. Joshua Schiffman, are using MIP technology to identify unique genetic aberrations that can distinguish between different types of pediatric cancers. Their work has uncovered patterns of copy number aberrations and regions of allelic imbalance that could be used to guide risk stratification and future treatment.
In 2009, Dr. Schiffman collaborated with Affymetrix using a 24K MIP panel and GeneChip® 30K Universal Tag Arrays to analyze 45 pediatric leukemia samples in order to detect unique copy number aberrations. Their study identified 69 regions of copy number changes, including unique patterns of copy number loss in samples with a deletion of the CDKN2A gene. These patterns differentiated between two similar subtypes of acute lymphoblastic leukemia (ALL), precursor B-cell ALL and precursor T-cell ALL. Recently, Schiffman and colleagues used Affymetrix MIP Copy Number Services to perform a genome-wide analysisof copy number alterations in different malignancy grades of pediatric astrocytomas. The study identified several genomic amplifications that characterized the different tumor grades. Specifically, the study revealed distinct BRAF gene rearrangements that occurred in grade 1 versus grade 2 to 4 tumors and indicated BRAF mutation as a frequent mutation target in pediatric astrocytomas. They also found that BRAF mutations were significantly associated with homozygous CDKN2A deletions, suggesting the possibility of a new subset of pediatric astrocytomas.
"With the MIP assay, we can easily correlate patient outcome with higher copy numbers," said Schiffman. "Once we collect enough samples and enough outcome data, we"ll better understand the relationship between high copy number value and clinical outcome in many different types of cancer." Schiffman recently spoke with Jessica Parra, Associate Marketing Manager at Affymetrix, about his use of the MIP copy number platform to study different forms of pediatric cancers. The two discussed:
- The advantages of being able to analyze formalin-fixed, paraffin-embedded (FFPE) samples
- The MIP copy number platform design and the linear dynamic range of the assay
- The clinical importance of being able to identify copy number changes that can characterize different forms of pediatric cancers
More Related Scientist Spotlights
- Jay Tiesman, PhD Procter & Gamble Company's Jay Tiesman, PhD, discusses the role of genomics in the cosmetics industry.
- Joshua Schiffman, MD The University of Utah's Joshua Schiffman, MD, discusses the use of molecular inversion probe (MIP) technology for studying copy number alterations in pediatric cancers.
- Avrum Spira, MD Boston University's Avrum Spira, MD, discusses the discovery of a gene expression signature and a potential preventative treatment for lung cancer.
- Lisa Baumbach, MD The University of Miami's Lisa Baumbach and Maastricht University's Torik Ayoubi discuss how ethnicity-specific genetic changes govern aggressive breast cancer risks.
- Chris Smith, PhD Chris Smith of Cambridge University, Tyson Clark of Affymetrix and Melissa Cline of UCSC discuss EURASNET's approach for comparing commercial microarrays.
- Robert Norgren, PhD Rob Norgren of The University of Nebraska Medical Center and Katja Nowick of Lawrence Livermore National Laboratory discuss the development of the Rhesus Macaque Genome Array.
- Yong-Jie Lu, PhD Yong-Jie Lu of Queen Mary, University of London and Colleen Elso of the Walter and Eliza Hall Institute discuss a method for rapidly identifying chromosome rearrangements.
- Scientist Spotlight (pdf, 206 KB) MIP Technology reveals important copy number changes in pediatric cancer
Human Spermatogenic Failure Purges Deleterious Mutation Load from the Autosomes and Both Sex Chromosomes, including the Gene DMRT1
Lopes, A. M.; Aston, K. I.; Thompson, E.; Carvalho, F.; Goncalves, J.; Huang, N.; Matthiesen, R.; Noordam, M. J.; Quintela, I.; Ramu, A.; Seabra, C.; Wilfert, A. B.; Dai, J. C.; Downie, J. M.; Fernandes, S.; Guo, X. J.; Sha, J. H.; Amorim, A.; Barros, A.; Carracedo, A.; Hu, Z. B.; Hurles, M. E.; Moskovtsev, S.; Ober, C.; Paduch, D. A.; Schiffman, J. D.; Schlegel, P. N.; Sousa, M.; Conrad, D. F. Plos Genetics 9(3), NPG, 2013 PubMed
Toward a more uniform sampling of human genetic diversity: A survey of worldwide populations by high-density genotyping
Xing, J.; Watkins, W. S.; Shlien, A.; Walker, E.; Huff, C. D.; Witherspoon, D. J.; Zhang, Y.; Simonson, T. S.; Weiss, R. B.; Schiffman, J. D.; Malkin, D.; Woodward, S. R.; Jorde, L. B. Genomics 96(4), 199-210, 2010 PubMed
Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemia
Schiffman, J. D.; Wang, Y.; McPherson, L. A.; Welch, K.; Zhang, N.; Davis, R.; Lacayo, N. J.; Dahl, G. V.; Faham, M.; Ford, J. M.; Ji, H. P. Cancer Genetics and Cytogenetics 193(1), 9-18, 2009 PubMed
Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease
Moore, D. F.; Goldin, E.; Gelderman, M. P.; Robinson, C.; Baer, J.; Ries, M.; Elkahloun, A.; Brady, R.; Schiffmann, R. Acta Paediatrica 97(Supplement 457), 48-52, 2008 PubMed
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
Ruckhaeberle, E.; Rody, A.; Engels, K.; Gaetje, R.; von Minckwitz, G.; Schiffmann, S.; Groesch, S.; Geisslinger, G.; Holtrich, U.; Karn, T.; Kaufmann, M. Breast Cancer Research and Treatment 112(1), 41-52, 2008 PubMed
Warning! The earliest signals for cancer - miRNA regulation
Featured Social Network
Covering personalized medicine, cancer research, pharmacogenomics, and more